According to a new report, published by KBV research, The Global Iliac Stent Market size is expected to reach $1.4 billion by 2030, rising at a market growth of 5.9% CAGR during the forecast period.
Iliac stents are used in the management of traumatic injuries to the iliac arteries, such as blunt or penetrating trauma, dissection, or pseudoaneurysm formation. Stenting of traumatic iliac artery injuries can help stabilize the arterial wall, restore blood flow, and prevent hemorrhage or limb ischemia in critically injured patients. The high prevalence of injuries is providing a growth avenue for the iliac stent market. For example, the World Health Organization (WHO) estimates that injuries, both unintentional and caused by violence, cause the deaths of 4.4 million people globally annually, or around 8% of all fatalities.
The iliac stent market is characterized by a dynamic landscape of trends and innovations driven by evolving clinical needs, technological advancements, and market forces. Key trends shaping the market include the development of next-generation stent platforms with enhanced radial strength, flexibility, and deliverability, enabling precise stent deployment and optimal lesion coverage in challenging anatomies. Likewise, the development of next-generation iliac stent platforms represents a major trend in the market, characterized by innovations in stent design, materials, and delivery systems.
The emergence of drug-eluting stents (DES) in the iliac stent market represents a significant innovation to reduce restenosis rates and improve long-term outcomes. DES are coated with anti-proliferative drugs that inhibit neointimal hyperplasia and reduce the risk of in-stent restenosis following stent placement. By releasing controlled doses of therapeutic agents directly to the vessel wall, DES offers targeted drug delivery and enhanced efficacy compared to bare-metal stents, improving patency rates and clinical outcomes in patients with iliac artery disease.
The Severe Calcified Lesions segment would exhibit a CAGR of 6.4% during (2023 - 2030). Patients with diabetes mellitus and chronic kidney disease (CKD) are at a higher risk of developing severe calcified lesions in their arteries. Both diabetes and renal disease are associated with accelerated atherosclerosis and vascular calcification, leading to the formation of dense, heavily calcified plaques in the iliac arteries. The increasing prevalence of diabetes and renal disease globally contributes to the rising incidence of severely calcified lesions in the iliac arteries.
The Hospitals segment is registering maximum revenue in the Global Iliac Stent Market by End-use in 2022; thereby, achieving a market value of $876 million by 2030. Hospitals are prepared to manage a variety of complicated cases, such as those involving patients with advanced or severe iliac artery disease who need difficult procedures like the implantation of iliac stents. Additionally, the expansion of the hospitals is providing a growth opportunity for the iliac stent market. For example, the National Investment Promotion and Facilitation Agency reports that domestic and foreign investors are showing a strong interest in investing in India’s hospital sector, which makes up 80% of the country’s total healthcare industry.
The Balloon-expandable Stents segment is experiencing a CAGR of 6.1% during (2023 - 2030). Balloon-expandable stents allow for precise deployment in the iliac arteries, offering controlled expansion and accurate positioning within the vessel lumen. Stent placement on a balloon catheter allows uniform expansion throughout the lesion site and ideal stent apposition to the artery wall. The balloon catheter is inflated to stretch the stent to the required diameter.
Full Report: https://www.kbvresearch.com/iliac-stent-market/
The North America region dominated the Global Iliac Stent Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $600 million by 2030. The Europe region is anticipated to grow at a CAGR of 5.5% during (2023 - 2030). Additionally, The Asia Pacific region would witness a CAGR of 6.8% during (2023 - 2030).
By Artery Lesions
By End-use
By Type
By Geography
Unique Offerings 
